Articles tagged "Immunosuppression"

2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
N. Kanaan,¹ C. Percy,¹ Z. Hassoun,² M. Mourad,³ C. Beguin,⁴ M. De Meyer,³ E. Goffin.¹
¹Nephrology, Cliniques Universitaires Saint Luc, Brussels, Belgium; ²Gastroenterology, Cliniques Universitaires Saint Luc, Brussels, Belgium; ³Abdominal Surgery and Transplantation, Cliniques Universitaires Saint Luc, Brussels, Belgium; ⁴Medical Information and Statistics, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…
2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
K. Sanghavi,¹ R. Brundage,¹ M. Miller,² D. Schaldt,³ A. Israni,³ W. Guan,⁴ W. Oetting,¹ R. Mannon,⁵ R. Remmel,¹ A. Matas,⁶ P. Jacobson.¹
¹College of Pharmacy, University of MN, Minneapolis, MN; ²Dept of Psychology, University of MN, Minneapolis, MN; ³Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, MN; ⁴Dept of Biostatistics, University of MN, Minneapolis, MN; ⁵Dept of Nephrology, University of AL, Birmingham, AL; ⁶Dept of Surgery, University of MN, Minneapolis, MN.
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…
2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
A. Alvarado,¹ A. Shetty,¹ O. Traitanon,¹ J. Leventhal,¹ V. Mas,² D. Chhabra,³ J. Matthews,¹ L. Gallon.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²University of Virgina, Charlottesville, Va; ³Advocate Christ Medical Center, Chicago, IL.
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…
2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2015 American Transplant Congress
Deceased Donor Kidney Transplantation Without Calcineurin Inhibitors or Steroids
A. Kirk,^1,2 A. Guasch,¹ S. Mead,¹ A. Ghali,¹ A. Mehta,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson.¹
¹Transplant Center, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
J. Espinosa,^1,2 L. Stempora,^1,2 R. Townsend,³ A. Kirk.^1,2
¹Duke University, Durham, NC; ²Emory University, Atlanta, GA; ³Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…
2015 American Transplant Congress
ASKP1240 in De Novo Kidney Transplant Recipients
R. Harland,¹ G. Klintmalm,² H. Yang,³ S. Jensik,⁴ T. Shah,⁵ P. West-Thielke,⁶ F. Shihab,⁷ W. Zhang,⁸ V. Santos,⁸ R. Tainaka,⁸ X. Wang,⁸ R. First,⁸ J. Holman.⁸
¹East Carolina University, Greenville, NC; ²Baylor University Medical Center, Dallas, TX; ³Pinnacle Health System, Harrisburg, PA; ⁴Rush University, Chicago, IL; ⁵Transplant Research Institute, Los Angeles, CA; ⁶University of Illinois Chicago, Chicago, IL; ⁷University of Utah Health Science Center, Salt Lake City, UT; ⁸Astellas Pharma Global Development, Northbrook, IL.
Primary objective was to evaluate the efficacy and safety of ASKP1240, antagonistic anti-CD40 antibody, in either a CNI free regimen or a CNI minimization regimen…
2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
T. Horwedel,¹ L. Bowman,¹ W. Chapman,² J. Hagopian.¹
¹Barnes-Jewish Hospital, St. Louis, MO; ²Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…
2015 American Transplant Congress
Immunomodulation of Human T Cells by a Novel RALG Preparation With Higher Specificity Toward Activating T Cells
K. Samy, H. Xu, A. Kirk.
Surgery, Duke University Medical Center, Durham, NC.
Current induction therapy using thymoglobulin (ATG) results in nonspecific T cell depletion. We have generated a polyclonal rabbit anti-human leukocyte globulin (RALG) by immunizing rabbits…
2015 American Transplant Congress
Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis
L. Weekers,¹ P. Erpicum,¹ O. Detry,³ C. Lechanteur,² E. Baudoux,² F. Jouret,¹ Y. Beguin.²
¹Nephrology, University Hospital of Liege, Liege, Belgium; ²Hematology, University Hospital of Liege, Liege, Belgium; ³Abdominal Surgery, University Hospital of Liege, Liege, Belgium.
Back-groundMesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents.We report the 6-month safety results for the 5 first patients treated…